Company Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.
It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.
Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Apr 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 649 |
| CEO | Kathryn Haviland |
Contact Details
Address: 45 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | (617) 374-7580 |
| Website | blueprintmedicines.com |
Stock Details
| Ticker Symbol | BPMC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001597264 |
| CUSIP Number | 09627Y109 |
| ISIN Number | US09627Y1091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kathryn Haviland M.B.A. | President, Chief Executive Officer and Director |
| Alexis A. Borisy A.M. | Co-Founder and Director |
| Michael Landsittel CPA | Chief Financial Officer |
| Christina Rossi M.B.A. | Chief Operating Officer |
| Dr. Percy H. Carter M.B.A., Ph.D. | Chief Scientific Officer |
| Dr. Fouad Namouni M.D. | President of Research and Development |
| Jenna Cohen | Senior Director and Head of Investor Relations |
| Debra Durso-Bumpus | Chief People Officer |
| Julian Charles Baker | Senior Vice President of Corporate Affairs |
| Ariel Hurley | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |
| Apr 1, 2025 | 144 | Filing |
| Mar 24, 2025 | 144 | Filing |
| Mar 6, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Feb 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2025 | 10-K | Annual Report |